| 1 |
35187743 | eIF3a-PPP2R5A-mediated ATM/ATR dephosphorylation is essential for irinotecan-induced DNA damage response. | 2022 Apr |
1 |
| 2 |
35231830 | Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study. | 2022 Apr 5 |
3 |
| 3 |
33407715 | Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. | 2021 Jan 6 |
3 |
| 4 |
31856090 | ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance. | 2020 Jan |
1 |
| 5 |
29963241 | Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. | 2018 Jun 12 |
1 |
| 6 |
30085332 | Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. | 2018 Oct |
2 |
| 7 |
30385821 | pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. | 2018 Nov |
1 |
| 8 |
27169843 | Aberrant BLM cytoplasmic expression associates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer. | 2017 Mar |
1 |
| 9 |
29340025 | The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. | 2017 Dec 19 |
3 |
| 10 |
27638859 | ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis. | 2016 Dec |
6 |
| 11 |
24934408 | Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. | 2014 Sep |
1 |